arrow
N

Nelli Bejanyan

Department of Blood and Marrow Transplantation and Cellular Immunotherapy
H指数:32
被引数:3,731

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A novel severe toxicity-free, and progression-free survival endpoint predicts outcomes after CD19 chimeric antigen receptor-T cell therapy in large B-cell lymphoma

一种新型无严重毒性、无进展生存期终点的预测指标可预测CD19嵌合抗原受体-T细胞疗法在大型B细胞淋巴瘤中的治疗效果

2026-07-170
OAAI
Expanded antigen-specific donor regulatory T cells for GVHD prevention

扩增的抗原特异性供者调节性T细胞用于GVHD预防

Blood
IF23.1
2026-06-220
PRE
Single center evaluation of a composite risk assessment model to predict non-relapse mortality following allogeneic hematopoietic cell transplantation (HCT)

单中心评估一种复合风险预测模型,用于预测异基因造血细胞移植(HCT)后的非复发死亡率。

2026-04-080
PRE
Post-transplant MRD Monitoring by TP53 Duplex Sequencing with APR-246 + Azacitidine Maintenance Predicts Outcomes

移植后微小残留病(MRD)通过TP53双测序结合APR-246 + 去氧氟尿苷维持治疗预测预后

2025-11-270
OAAI
Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia

肥胖及基于体重的化疗剂量调整对急性髓系白血病异基因造血细胞移植结局的影响

2025-10-200
PRE
Trial of Enasidenib Maintenance Post Allogeneic Hematopoietic Cell Transplant in Patients With IDH-2 Mutated AML

在IDH-2突变急性髓系白血病异基因造血细胞移植后使用enasidenib维持治疗的试验

2025-09-190
PRE
Letermovir reduces cytomegalovirus in HLA-matched and mismatched allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide

Letermovir可降低接受移植后环磷酰胺治疗的HLA匹配和错配异基因造血细胞移植患者中的巨细胞病毒水平。

2025-07-050
PRE
ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA Antibodies
2024-12-013
PRE
Allogeneic Hematopoietic Cell Transplantation for the Treatment of Severe Aplastic Anemia: Evidence-Based Guidelines From the American Society for Transplantation and Cellular Therapy

异基因造血干细胞移植治疗重型再生障碍性贫血: 美国移植与细胞治疗学会循证指南

2024-12-011
OAAI
Melphalan Dose in Combination With Fludarabine Affects Gastrointestinal Toxicity and Graft-Versus-Host Disease After Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes

美法仑剂量联合氟达拉滨影响急性髓系白血病和骨髓增生异常综合征异基因移植后胃肠道毒性和移植物抗宿主病

2024-11-010
PRE
Lower Weight-Based Mycophenolate Mofetil Dosing is Associated with Superior Outcomes after Haploidentical Hematopoietic Cell Transplant with Post-transplant Cyclophosphamide
2024-10-011
PRE
Outcomes of Haploidentical Stem Cell Transplant Recipients With HHV-6B Reactivation

HHV-6B再激活的单倍体干细胞移植受者的结果

2024-09-260
OAAI
Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study
2024-08-142
OAAI
Mismatched donor allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide achieves comparable outcomes between racially and ethnically diverse patient populations
2024-03-280
OAAI
Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide
2024-02-015
PRE
Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis
2023-11-177
OAAI
Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patients (oct, 10.1038/s41375-022-01738-3, 2022)
LEUKEMIA
IF13.4
2023-03-220
OA
Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines
2023-02-0129
OAAI